BioVie Inc. shares have traded in a relatively tight range around the low single digits over the past 30 days. The stock closed near $1.13 in mid-November, a modest decline from the roughly $1.16 level recorded about a month earlier. That muted headline change, however, understates the underlying turbulence. On November 3, the stock spiked to an intraday high near $2.66 on elevated volume before surrendering most of those gains, a move that coincided with the company pricing a $4.74 million registered direct offering and concurrent private placement. The episode illustrates how a micro-cap, clinical-stage biotech can experience rapid price swings tied to financing activity as much as to clinical news. As a pre-revenue developer with no commercial products, BioVie's share price remains closely tied to pipeline milestones, data presentations, and its ability to secure capital. I also checked this using Tickeron’s AI Pattern Search Engine to see how the volatility compares across similar names.
BioVie is a clinical-stage biopharmaceutical company based in Carson City, Nevada, focused on developing therapies for neurological and neurodegenerative disorders and advanced liver disease. Its lead asset, bezisterim (formerly NE3107), is an investigational oral small molecule that crosses the blood-brain barrier and targets neuroinflammation and insulin resistance. The candidate is being evaluated across multiple indications, including Parkinson's disease, Alzheimer's disease, and long COVID. In liver disease, BioVie is advancing BIV201, a continuous-infusion formulation of terlipressin, for the treatment of ascites related to advanced liver cirrhosis; the program has received Orphan Drug and Fast Track designations from the FDA. Because the company has not yet generated product revenue, investors follow the stock primarily for its clinical readouts, regulatory progress, and funding strategy rather than traditional financial metrics. From what I see, this focus keeps attention squarely on upcoming data points.
The past 30 days have been defined by a steady cadence of bezisterim data presentations rather than any single dominant catalyst. In late October and November, BioVie presented new biomarker data from its Phase 2 ADDRESS-LC long COVID trial at the NIH's RECOVER-TLC workshop, highlighted Parkinson's disease findings at the American Neurological Association annual meeting, and announced an invitation to present Parkinson's data at the AD/PD 2027 conference. On the financing side, the company priced a $4.74 million registered direct offering and concurrent private placement in early November, adding to shareholder dilution and weighing on the share price after an initial spike. These events reflect the core tension in BioVie's story: encouraging but early clinical signals are being balanced against recurring capital raises that pressure the stock. I reviewed comparable setups with Tickeron’s AI Daily Buy/Sell Signals to contextualize the reaction.
Looking ahead, the central question for BioVie is whether bezisterim can translate early clinical signals into a registrational path. Management has indicated plans to pursue an end-of-Phase-2 meeting with the FDA for Parkinson's disease, with a potential pivotal Phase 3 trial under consideration. Additional long COVID data readouts and presentations are expected, while the launch of new Alzheimer's and ascites Phase 3 programs remains contingent on securing funding. Investors should monitor several factors: continued data disclosures, the company's cash runway and any further equity raises, progress toward regulatory interactions, and broader biotech sentiment. Financial risk remains material, as BioVie reported a net loss of about $22.1 million for the fiscal year ended June 30, 2026, with cash of roughly $9.0 million and a going-concern disclosure in its filings. These are factual considerations for anyone evaluating the stock, not financial advice or a prediction of future performance.
In my own process, I often turn to Tickeron’s AI Trading Bots to monitor how automated strategies respond to swings in clinical-stage names. The platform lets users explore hundreds of bots across strategies and timeframes, with top performers highlighted for quick review. This approach complements traditional analysis by showing data-driven positioning across the broader market without replacing individual due diligence.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BIVI advanced for three days, in 194 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BIVI's RSI Oscillator exited the oversold zone, 27 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BIVI as a result. In 83 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for BIVI turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 39 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
BIVI moved below its 50-day moving average on November 04, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for BIVI moved below the 200-day moving average on November 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
BIVI broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BIVI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.105) is normal, around the industry mean (3.498). P/E Ratio (-0.436) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. BIVI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIVI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology